NGEN

Nervgen Pharma Corp

• TipRanks·2d ago

  NervGen Pharma price target raised to $12 from $10 at Maxim

• Reuters·3d ago

  BUZZ-U.S. STOCKS ON THE MOVE-Apple, Intel, Alignment Healthcare

• Reuters·3d ago

  BUZZ-U.S. STOCKS ON THE MOVE -Health insurers, Arista, Savara

• TipRanks·3d ago

  NervGen Wins FDA Alignment for Phase 3 RESTORE Trial in Chronic Tetraplegia

• Reuters·3d ago

  BUZZ-NervGen rises after FDA backs late-stage study to test drug for spinal cord injury

• TipRanks·3d ago

  NervGen Pharma aligns with FDA on RESTORE study following End-of-Phase 2 meeting

• Reuters·3d ago

  NervGen wins FDA alignment for Phase 3 NVG-291 trial in chronic tetraplegia

• Benzinga·3d ago

  NervGen Pharma Completes End-Of-Phase 2 Meeting With FDA, Restores Phase 3 Registrational Trial To Evaluate NVG-291 To Treat Chronic Tetraplegia

• Reuters·3d ago

  NERVGEN PHARMA CORP - TO CONCLUDE ENROLLMENT IN PHASE 1B/2A CONNECT SCI SUBACUTE TETRAPLEGIA AND UNBLIND DATA

• TipRanks·4d ago

  NervGen Pharma price target lowered to $5.50 from $6.75 at Stifel

• TipRanks·04/02 19:00

  Analysts Offer Insights on Healthcare Companies: Milestone Scientific (MLSS) and NervGen Pharma (NGEN)

• TipRanks·04/01 19:25

  NervGen Pharma: Buy Rating on De‑Risked Path to Pivotal NVG-291 Trials and Compelling Risk‑Reward in Chronic Spinal Cord Injury

• Reuters·03/31 21:36

  NervGen FY25 net loss widens to $44.1 million; cash and investments climb to $22 million

• TipRanks·03/31 17:23

  NervGen Maps Path to Phase 3 as NVG-291 Data Strengthen Neuroreparative Ambitions

• Seeking Alpha·03/31 13:21

  NervGen Pharma FY GAAP EPS of -$0.61